Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer’s agitation medications.
A study conducted by researchers from Johns Hopkins University School of Medicine and Tufts University School of Medicine found that a pill form of dronabinol, an FDA-approved synthetic version of THC (the main ingredient in marijuana), reduces agitation in Alzheimer’s patients by an average of 30%.
The researchers say that compared to current treatments for agitation, such as antipsychotics, dronabinol produced similar calming effects without adverse results such as delirium or seizures.
Results of the eight-year clinical trial were presented at the International Psychogeriatric Association conference in Buenos Aires, Argentina, on Sept. 26.“These new findings represent eight years of work dedicated to people who have Alzheimer’s as well as their caregivers,” says Paul Rosenberg, M.D., professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine and co-principal investigator for this study. “Agitation is one of the most distressing symptoms of Alzheimer’s dementia, and we are pleased to make positive strides forward in the treatment of these patients.”
Alzheimer’s Agitation and the Need for New Treatments
Alzheimer’s disease is the most common neurodegenerative disease in the United States, with an estimated 6.7 million cases in Americans age 65 and older, according to the National Institutes of Health. This number is predicted to grow to 13.8 million by 2060. Agitation is difficult to manage. It is defined as excess motor activity (pacing or repetitive movements), verbal aggression, and/or physical aggression. An estimated 40% of people with Alzheimer’s develop agitation.
Although mild agitation can sometimes be moderated by behavioral intervention, in moderate to severe cases, some form of medication is typically required to manage symptoms and provide relief for caregivers.“It is the agitation, not the memory loss, that often drives individuals with dementia to the emergency department and long-term-care facilities,” says Brent Forester, M.D., psychiatrist-in-chief and chairman of the Department of Psychiatry at Tufts Medical Center and co-principal investigator on the study. “Dronabinol has the potential to both reduce health care costs and make an important, positive impact on caregivers’ mental and physical health.”
In the new study, researchers recruited 75 patients with severe Alzheimer’s agitation across five clinical sites, including 35 admitted to The Johns Hopkins Hospital between March 2017 and May 2024. To qualify, patients had to have a formal clinical diagnosis of Alzheimer’s disease and show at least one major symptom of agitation for at least two weeks. Prior to treatment, patients were tested for agitation using the Pittsburgh Agitation Scale (PAS) and the Neuropsychiatric Inventory Agitation/Aggression subscale (NPI-C).
The PAS scores agitation from 0 to 4, with 4 being the most agitated. The NPI-C provides a brief assessment of neuropsychiatric symptoms including delusions, hallucinations, anxiety/depression, and other factors. Baseline scores were acquired from caregivers at the onset of the trial.
Participants were then randomly selected to get either 5 milligrams of dronabinol in pill form or a placebo in pill form twice daily for three weeks, and then retested using the PAS and NPI-C.
Future Research and Cautions
Results from the dronabinol group show an average PAS starting value of 9.68 and an end value of 7.26 after three weeks, a 30% decrease compared to the scores in the placebo group which did not change. Additionally, dronabinol was well tolerated by patients compared to current treatments for agitation.“Results like this are encouraging. We are thrilled that FDA-approved dronabinol was robustly effective and appeared safe for treatment of agitation,” says Rosenberg. “This adds another tool in our efforts to improve the care of our loved ones with Alzheimer’s disease.”
The researchers say they plan longer-term studies of dronabinol for Alzheimer’s disease, as well as expanded sample sizes. They also hope to continue to explore other ways medical cannabis can benefit both patients and caregivers.
Dronabinol is a synthetic form of THC, the psychoactive main ingredient in cannabis (marijuana). The drug was approved by the U.S. Food and Drug Administration in 1985 to treat loss of appetite in patients with HIV/AIDS, and is currently prescribed to treat nausea and vomiting in those undergoing cancer chemotherapy.
The investigators caution that their current study results are not intended to encourage or inform the use of other forms of medical marijuana available in 38 states and the District of Columbia.
Meeting: International Psychogeriatric Association conference
Co-investigators include Halima Amjad, Haroon Burhanullah and Milap Nowrangi at the Johns Hopkins University School of Medicine, Marc Agronin at Miami Jewish Health, and James Wilkins and David Harper at McLean Hospital.
The study was funded by a grant from the National Institute of Aging at the National Institutes of Health.
News
New nanosystem offers hope for improved diagnosis and treatment of tongue cancer
A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and treatment of tongue squamous cell carcinoma (TSCC). By harnessing gold nanoparticles coupled with the HN-1 peptide, [...]
Global Trust in Science Is Stronger Than Expected – What’s Next?
A landmark global survey conducted across 68 countries has found that public trust in scientists remains robust, with significant support for their active involvement in societal and political matters. The study highlights the public’s [...]
Microplastics in the bloodstream may pose hidden risks to brain health
In a recent study published in the journal Science Advances, researchers investigated the impact of microplastics on blood flow and neurobehavioral functions in mice. Using advanced imaging techniques, they observed that microplastics obstruct cerebral blood [...]
AI Surveillance: New Study Exposes Hidden Risks to Your Privacy
A new mathematical model enhances the evaluation of AI identification risks, offering a scalable solution to balance technological benefits with privacy protection. AI tools are increasingly used to track and monitor people both online [...]
Permafrost Thaw: Unleashing Ancient Pathogens and Greenhouse Gases
Permafrost is a fascinating yet alarming natural phenomenon. It refers to ground that remains frozen for at least two consecutive years. Mostly found in polar regions like Siberia, Alaska, and Canada, permafrost plays a [...]
Frequent social media use tied to higher levels of irritability
A survey led by researchers from the Center for Quantitative Health at Massachusetts General Hospital and Harvard Medical School has analyzed the association between self-reported social media use and irritability among US adults. Frequent [...]
Australian oysters’ blood could hold key to fighting drug-resistant superbugs
Protein found in Sydney rock oysters’ haemolymph can kill bacteria and boost some antibiotics’ effectiveness, scientists discover An antimicrobial protein found in the blood of an Australian oyster could help in the fight against [...]
First U.S. H5N1 Death Sparks Urgency: Scientists Warn Bird Flu Is Mutating Faster Than Expected
A human strain of H5N1 bird flu isolated in Texas shows mutations enabling better replication in human cells and causing more severe disease in mice compared to a bovine strain. While the virus isn’t [...]
AI Breakthrough in Nanotechnology Shatters Limits of Precision
At TU Graz, a pioneering research group is leveraging artificial intelligence to drastically enhance the way nanostructures are constructed. They aim to develop a self-learning AI system that can autonomously position molecules with unprecedented precision, potentially [...]
How Missing Sleep Lets Bad Memories Haunt Your Mind
Research reveals that a lack of sleep can hinder the brain’s ability to suppress unwanted memories and intrusive thoughts, emphasizing the importance of restful sleep for mental health. Sleep deprivation has been found to [...]
WHO issues new warning over ‘mystery virus’ and calls for return of COVID restrictions
The World Health Organization (WHO) has called for the reinstatement of restrictions implemented during the COVID-19 pandemic as cases of human metapneumovirus (HMPV) continue to surge. While hospitals in China are overwhelmed with positive [...]
A Breath Away From a Cure: How Xenon Gas Could Transform Alzheimer’s Treatment
A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ability to mitigate brain damage and improve cognitive functions in mouse models. A forthcoming clinical trial aims to test its [...]
False Memories Under Fire: Surprising Science Behind What We Really Recall
New research challenges the ease of implanting false memories, highlighting flaws in the influential “Lost in the Mall” study. By reexamining the data from a previous study, researchers found that many supposed false memories [...]
Born Different? Cambridge Scientists Uncover Innate Sex Differences in Brains
Cambridge researchers found that sex differences in brain structure exist from birth, with males having more white matter and females more grey matter, highlighting early neurodiversity. Research from the Autism Research Centre at the University [...]
New study shows risk factors for dementia – virus causes deposits in the brain
Research into the causes of Alzheimer's is not yet complete. Now a new study shows that head trauma can activate herpes viruses and promote the disease. Frankfurt am Main – As a neurodegenerative disease, [...]
Are Machines Truly Thinking? Modern AI Systems Have Finally Achieved Turing’s Vision
Modern AI systems have fulfilled Turing’s vision of machines that learn and converse like humans, but challenges remain. A new paper highlights concerns about energy consumption and societal inequality while calling for more robust [...]
